Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

HMGA2 Gene Expression Profile Improves Risk Stratification in Acute Myeloid Leukemia

Miriam Marquis, PhD, Cyrielle Beaubois, Vincent-Philippe Lavallee, MD, Michal Abrahamowicz, PhD, Coraline Danieli, PhD, Sébastien Lemieux, PhD, Imran Ahmad, MD, Andrew Wei, MBBS, FRACP, FRCPA, PhD, Stephen B Ting, MD PhD, Shaun Fleming, MBBS(Hons) FRACP FRCPA, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, William Grey, PhD, David Grimwade, MD PhD, Robert K. Hills, DPhil, Paresh Vyas, MD PhD, Nigel H. Russell, MD, Guy Sauvageau, MD, PhD, Josee Hebert, MD

Blood (2017) 130 (Supplement 1): 1402.

https://doi.org/10.1182/blood.V130.Suppl_1.1402.1402

Published: 2017

Journal Articles

Characteristics and Outcome of Patients with Acute Myeloid Leukemia and t(6;9)(p22;q34)

Blood (2017) 130 (Supplement 1): 3906.

https://doi.org/10.1182/blood.V130.Suppl_1.3906.3906

Published: 2017

Journal Articles

An Evaluation of 17 Years of Low Dose Cytarabine As Therapy for AML Patients Not Fit for Intensive Treatment, Including Patients with Adverse Cytogenetics, Shows Improving Survival, Potential Underutilisation and Highlights the Need for New Therapy

Michael Dennis, MDMRCP,FRCPath, Robert K. Hills, DPhil, Nigel H. Russell, Mhairi Copland, PhD MBBChir, FRCP, FRCPath, Ian Thomas, Mary Frances Frances McMullin, MB,Bch BAO, MD FRCPath, Sahra Ali, Alan K. Burnett, MD

Blood (2017) 130 (Supplement 1): 3874.

https://doi.org/10.1182/blood.V130.Suppl_1.3874.3874

Published: 2017

Journal Articles

Flow Cytometric Minimal Residual Disease As Risk Stratification Tool in Younger Adults with NPM1 Wild Type Standard Risk Acute Myeloid Leukemia

Sylvie D Freeman, MBChB, DPhil, Robert K. Hills, DPhil, Paul Virgo, Naeem Khan, PhD, Stephen Couzens, Richard James Dillon, MA, PhD MRCP, FRCPath, Laura Upton, Lars Kjeldsen, MD, Ian Thomas, David Grimwade, Alan K. Burnett, MD, Nigel H. Russell

Blood (2017) 130 (Supplement 1): 468.

https://doi.org/10.1182/blood.V130.Suppl_1.468.468

Published: 2017

Journal Articles

A Knowledge-Based Approach for Clinical Annotation of Oncogenic Variants to Support Patient-Tailored Diagnosis in Myeloid Disease

Blood (2017) 130 (Supplement 1): 1414.

https://doi.org/10.1182/blood.V130.Suppl_1.1414.1414

Published: 2017

Journal Articles

A Randomised Assessment of Ganetespib Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia: Results of the LI-1 Trial

Michael Dennis, FRCPath, Robert K Hills, DPhil, Ian Thomas, Sunil Gupta, MBBS, MRCP, FRCPath, Nicki Panoskaltsis, MD, Mhairi Copland, PhD BSc, MB, ChB, MRCP, FRCPath, Alan K. Burnett, MD FRCP, Nigel H Russell, MD

Blood (2016) 128 (22): 2827.

https://doi.org/10.1182/blood.V128.22.2827.2827

Published: 2016

Journal Articles

Axl/ Mer Inhibitor ONO-9330547 As a Novel Therapeutic Agent in a Stromal Co-Culture Model of Primary Acute Myeloid Leukaemia (AML)

Marie Gilmour, PhD, Anna Scholtz, Oliver G. Ottmann, MD, Robert K Hills, DPhil, Steven Knapper, Joanna Zabkiewicz, PhD

Blood (2016) 128 (22): 2754.

https://doi.org/10.1182/blood.V128.22.2754.2754

Published: 2016

Journal Articles

Long Term Follow up from the NCRI AML17 Trial of Attenuated Arsenic Trioxide and ATRA Therapy for Newly Diagnosed and Relapsed Acute Promyelocytic Leukaemia

Nigel H Russell, MD, Alan K. Burnett, MD FRCP, Robert K Hills, DPhil, Sophie Betteridge, PhD, Michael Dennis, FRCPath, Richard Dillon, MA, MRCP, FRCPath, David Grimwade, PhD FRCPath

Blood (2016) 128 (22): 897.

https://doi.org/10.1182/blood.V128.22.897.897

Published: 2016

Journal Articles

Pml Nuclear Body Disruption Cooperates in APL Pathogenesis, Impacting DNA Damage Repair Pathways

Edwige Voisset, PhD, Eva Moravcsik, Eva W Stratford, Amie Jaye, Christopher J Palgrave, Robert K Hills, DPhil, Paolo Salomoni, Scott C. Kogan, MD, Ellen Solomon, David Grimwade, PhD FRCPath

Blood (2016) 128 (22): 742.

https://doi.org/10.1182/blood.V128.22.742.742

Published: 2016

Journal Articles

HFE Gene Mutation Status Predicts Response to Gemtuzumab Ozogamicin in AML

Etienne Paubelle, Alice Marceau, Florence Zylbersztejn, Mickael Dussiot, Ivan Cruz Moura, PhD, Pascale Cornillet-Lefebvre, MD, Jacques Delaunay, MD, Alan K. Burnett, Sylvie Castaigne, Philippe Guardiola, MD, Norbert Ifrah, MD PhD, Hervé Dombret, Claude Preudhomme, Robert K Hills, DPhil, Olivier Hermine

Blood (2015) 126 (23): 1307.

https://doi.org/10.1182/blood.V126.23.1307.1307

Published: 2015

Journal Articles

PP2A Inhibition By CIP2A or SETBP1 Leads to Elevated Levels of AKT S473 Which Can be Used As a Biomarker of Outcome in Acute Myeloid Leukaemia

Robert K Hills, DPhil, Claire M Lucas, Laura J Scott, Natasha Carmell, Alison K Holcroft, Richard E. Clark, MD

Blood (2015) 126 (23): 1396.

https://doi.org/10.1182/blood.V126.23.1396.1396

Published: 2015

Journal Articles

Quizartinib Significantly Improves Overall Survival in FLT3-ITD Positive AML Patients Relapsed after Stem Cell Transplantation or after Failure of Salvage Chemotherapy: A Comparison with Historical AML Database (UK NCRI data)

Robert K Hills, DPhil, Guy Gammon, MBBS,MRCP, Denise Trone, Alan K. Burnett, MD FRCP

Blood (2015) 126 (23): 2557.

https://doi.org/10.1182/blood.V126.23.2557.2557

Published: 2015

Journal Articles

A Comparison of 1 or 2 Courses of High Dose Cytarabine As Consolidation in Younger Patients with AML: First Results of the UK NCRI AML17 Trial

Nigel H. Russell, MD, Robert K Hills, DPhil, Sylvie Freeman, PhDFRCPath, Steven Knapper, Lars Kjeldsen, MD PhD, Ian Thomas, Jamie Cavenagh, Paul Cahalin, Mary Frances McMullin, MD FRCPath, FRCP, Alan K. Burnett, MD FRCP

Blood (2015) 126 (23): 221.

https://doi.org/10.1182/blood.V126.23.221.221

Published: 2015

Journal Articles

An Operational Definition of Primary Refractory Acute Myeloid Leukaemia Which Allows Early Identification of Patients for Whom Allogeneic Stem Cell Transplantation Represents the Only Curative Therapy

Paul Ferguson, MBChB MRCP PhD, Robert K Hills, DPhil, Angela Grech, Sophie Betteridge, Lars Kjeldsen, MD PhD, Michael Dennis, FRCPath, Paresh Vyas, MD PhD, Alan K. Burnett, MD FRCP, Anthony H. Goldstone, FRCP, FRCPath, Donald Milligan, MD, Richard E. Clark, MD, Nigel H. Russell, MD, Charles Craddock, MDPhD

Blood (2015) 126 (23): 559.

https://doi.org/10.1182/blood.V126.23.559.559

Published: 2015

Journal Articles

Idarubicin and ATRA Is as Effective as MRC Chemotherapy in Patients with Acute Promyelocytic Leukaemia with Lower Toxicity and Resource Usage: Preliminary Results of the MRC AML15 Trial.

Alan K. Burnett, MD, Robert K. Hills, DPhil, David Grimwade, MD, Anthony H. Goldstone, MD, Ann Hunter, MD, Don Milligan, MD, Archie G. Prentice, MD, Nigel H. Russell, MD, Keith Wheatley, DPhil

Blood (2007) 110 (11): 589.

https://doi.org/10.1182/blood.V110.11.589.589

Published: 2007

Journal Articles

Prognostic Factors in Older AML Patients Receiving Intensive and Non-Intensive Therapy: Analysis of the UK AML11 and AML14 Trials.

Keith Wheatley, DPhil, Cassey L. Brookes, MSc, Robert K. Hills, DPhil, Anthony H. Goldstone, FRCP, Donald W. Milligan, MD, Archie G. Prentice, Anthony V. Moorman, PhD, Alan K. Burnett

Blood (2005) 106 (11): 674.

https://doi.org/10.1182/blood.V106.11.674.674

Published: 2005

Journal Articles

Meta-Analyses of Randomised Controlled Trials (RCT) of Warfarin and Low Molecular Weight Heparin (LMWH) for the Prevention of Venous Thromboembolism (VTE) and Death in Cancer Patients.

Keith Wheatley, DPhil, Laura E. Gross, DPhil, Robert K. Hills, DPhil, Annie M. Young, BSc, RGN

Blood (2005) 106 (11): 909.

https://doi.org/10.1182/blood.V106.11.909.909

Published: 2005

NARROW

HMGA2 Gene Expression Profile Improves Risk Stratification in Acute Myeloid Leukemia

Characteristics and Outcome of Patients with Acute Myeloid Leukemia and t(6;9)(p22;q34)

An Evaluation of 17 Years of Low Dose Cytarabine As Therapy for AML Patients Not Fit for Intensive Treatment, Including Patients with Adverse Cytogenetics, Shows Improving Survival, Potential Underutilisation and Highlights the Need for New Therapy

Flow Cytometric Minimal Residual Disease As Risk Stratification Tool in Younger Adults with NPM1 Wild Type Standard Risk Acute Myeloid Leukemia

A Knowledge-Based Approach for Clinical Annotation of Oncogenic Variants to Support Patient-Tailored Diagnosis in Myeloid Disease

A Randomised Assessment of Ganetespib Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia: Results of the LI-1 Trial

Axl/ Mer Inhibitor ONO-9330547 As a Novel Therapeutic Agent in a Stromal Co-Culture Model of Primary Acute Myeloid Leukaemia (AML)

Long Term Follow up from the NCRI AML17 Trial of Attenuated Arsenic Trioxide and ATRA Therapy for Newly Diagnosed and Relapsed Acute Promyelocytic Leukaemia

Pml Nuclear Body Disruption Cooperates in APL Pathogenesis, Impacting DNA Damage Repair Pathways

HFE Gene Mutation Status Predicts Response to Gemtuzumab Ozogamicin in AML

PP2A Inhibition By CIP2A or SETBP1 Leads to Elevated Levels of AKT S473 Which Can be Used As a Biomarker of Outcome in Acute Myeloid Leukaemia

Quizartinib Significantly Improves Overall Survival in FLT3-ITD Positive AML Patients Relapsed after Stem Cell Transplantation or after Failure of Salvage Chemotherapy: A Comparison with Historical AML Database (UK NCRI data)

A Comparison of 1 or 2 Courses of High Dose Cytarabine As Consolidation in Younger Patients with AML: First Results of the UK NCRI AML17 Trial

An Operational Definition of Primary Refractory Acute Myeloid Leukaemia Which Allows Early Identification of Patients for Whom Allogeneic Stem Cell Transplantation Represents the Only Curative Therapy

Idarubicin and ATRA Is as Effective as MRC Chemotherapy in Patients with Acute Promyelocytic Leukaemia with Lower Toxicity and Resource Usage: Preliminary Results of the MRC AML15 Trial.

Prognostic Factors in Older AML Patients Receiving Intensive and Non-Intensive Therapy: Analysis of the UK AML11 and AML14 Trials.

Meta-Analyses of Randomised Controlled Trials (RCT) of Warfarin and Low Molecular Weight Heparin (LMWH) for the Prevention of Venous Thromboembolism (VTE) and Death in Cancer Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only